These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 30503378)

  • 21. Investigating the Role of Altered Systemic Albumin Concentration on the Disposition of Theophylline in Adult and Pediatric Patients with Asthma by Using the Physiologically Based Pharmacokinetic Approach.
    Rasool MF; Khalid R; Imran I; Majeed A; Saeed H; Alasmari F; Alanazi MM; Alqahtani F
    Drug Metab Dispos; 2020 Jul; 48(7):570-579. PubMed ID: 32393652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of a multiroute physiologically based pharmacokinetic model for orbifloxacin in rabbits.
    Yang F; Yang F; Shi W; Si H; Kong T; Wang G; Zhang J
    J Vet Pharmacol Ther; 2018 Aug; 41(4):622-631. PubMed ID: 29457247
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population Pharmacokinetics of Finafloxacin in Healthy Volunteers and Patients with Complicated Urinary Tract Infections.
    Taubert M; Lückermann M; Vente A; Dalhoff A; Fuhr U
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29339394
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs.
    Björkman S
    Br J Clin Pharmacol; 2005 Jun; 59(6):691-704. PubMed ID: 15948934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ciprofloxacin in management of urinary tract infection.
    Tolkoff-Rubin NE; Rubin RH
    Urology; 1988 Apr; 31(4):359-67. PubMed ID: 3281368
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of ciprofloxacin versus use of aminoglycosides for therapy of complicated urinary tract infection: prospective, randomized clinical and pharmacokinetic study.
    Fang GD; Brennen C; Wagener M; Swanson D; Hilf M; Zadecky L; DeVine J; Yu VL
    Antimicrob Agents Chemother; 1991 Sep; 35(9):1849-55. PubMed ID: 1952856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Explorative Randomized Phase II Clinical Study of the Efficacy and Safety of Finafloxacin versus Ciprofloxacin for Treatment of Complicated Urinary Tract Infections.
    Wagenlehner F; Nowicki M; Bentley C; Lückermann M; Wohlert S; Fischer C; Vente A; Naber K; Dalhoff A
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29339395
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population Pharmacokinetic Analyses for Plazomicin Using Pooled Data from Phase 1, 2, and 3 Clinical Studies.
    Trang M; Seroogy JD; Van Wart SA; Bhavnani SM; Kim A; Gibbons JA; Ambrose PG; Rubino CM
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670433
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically-based pharmacokinetic modelling: application to docetaxel.
    Thai HT; Mazuir F; Cartot-Cotton S; Veyrat-Follet C
    Br J Clin Pharmacol; 2015 Sep; 80(3):534-47. PubMed ID: 26095234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retrospective observational study to assess the clinical management and outcomes of hospitalised patients with complicated urinary tract infection in countries with high prevalence of multidrug resistant Gram-negative bacteria (RESCUING).
    Shaw E; Addy I; Stoddart M; Vank C; Grier S; Wiegand I; Leibovici L; Eliakim-Raz N; Vallejo-Torres L; Morris S; MacGowan A; Carratalà J; Pujol M;
    BMJ Open; 2016 Jul; 6(7):e011500. PubMed ID: 27473949
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacodynamics of Finafloxacin, Ciprofloxacin, and Levofloxacin in Serum and Urine against TEM- and SHV-Type Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae Isolates from Patients with Urinary Tract Infections.
    Dalhoff A; Schubert S; Vente A
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28193648
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals.
    Schlender JF; Meyer M; Thelen K; Krauss M; Willmann S; Eissing T; Jaehde U
    Clin Pharmacokinet; 2016 Dec; 55(12):1573-1589. PubMed ID: 27351180
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Application of Fluoroquinolone Resistance Score in Management of Complicated Urinary Tract Infections.
    Shah A; Justo JA; Bookstaver PB; Kohn J; Albrecht H; Al-Hasan MN
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28193655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Physiologically Based Pharmacokinetic Modeling of Oxycodone in Children to Support Pediatric Dosing Optimization.
    Zheng L; Xu M; Tang SW; Song HX; Jiang XH; Wang L
    Pharm Res; 2019 Oct; 36(12):171. PubMed ID: 31654287
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Urinary excretion and bactericidal activity of intravenous ciprofloxacin compared with oral ciprofloxacin.
    Naber KG; Theuretzbacher U; Moneva-Koucheva G; Stass H
    Eur J Clin Microbiol Infect Dis; 1999 Nov; 18(11):783-9. PubMed ID: 10614952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of sparfloxacin and ciprofloxacin in the treatment of community-acquired acute uncomplicated urinary tract infection in women. Sparfloxacin Multicenter Uncomplicated Urinary Tract Infection Study Group.
    Henry DC; Nenad RC; Iravani A; Tice AD; Mansfield DL; Magner DJ; Dorr MB; Talbot GH
    Clin Ther; 1999 Jun; 21(6):966-81. PubMed ID: 10440621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population pharmacokinetic analysis of ciprofloxacin in the elderly patients with lower respiratory tract infections.
    Cios A; Wyska E; Szymura-Oleksiak J; Grodzicki T
    Exp Gerontol; 2014 Sep; 57():107-13. PubMed ID: 24862289
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does moderate renal impairment affect clinical outcomes in complicated intra-abdominal and complicated urinary tract infections? Analysis of two randomized controlled trials with ceftolozane/tazobactam.
    Kullar R; Wagenlehner FM; Popejoy MW; Long J; Yu B; Goldstein EJ
    J Antimicrob Chemother; 2017 Mar; 72(3):900-905. PubMed ID: 27999024
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of a once-daily treatment using ciprofloxacin in an extended-release dosage form.
    Schuck EL; Dalhoff A; Stass H; Derendorf H
    Infection; 2005 Dec; 33 Suppl 2():22-8. PubMed ID: 16518708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients.
    Roger C; Wallis SC; Louart B; Lefrant JY; Lipman J; Muller L; Roberts JA
    J Antimicrob Chemother; 2016 Jun; 71(6):1643-50. PubMed ID: 26957490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.